Gabriella Wojewodka

TL;DR: Quality of Life (QoL) is the preferred outcome in non-pharmacological trials, but there is little UK population evidence of QoL in epilepsy and developing and evaluating ways to reduce psychological and social disadvantage are likely to be of primary importance.

TL;DR: The cost-effectiveness study showed that SMILE (UK) was possibly cost-effective but was also associated with lower QoL, whereas for people with epilepsy and persistent seizures, a 2-day self-management education course is cost-saving, but does not improve quality of life after 12-months or reduce anxiety or depression symptoms.

TL;DR: There were significant improvements in quality of life scales and seizure frequency in many of the interventions, however, considerable heterogeneity of interventions and outcomes made comparison between the studies difficult.

TL;DR: Evaluated a group self‐management education courses for people with epilepsy and drug‐resistant seizures by means of a multicenter, pragmatic, parallel group, randomized controlled trial.

TL;DR: The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes and may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplements in people with psychosis.